Immutep (IMMP) Receives Daily News Sentiment Rating of 0.26

Media coverage about Immutep (NASDAQ:IMMP) has trended positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immutep earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 48.3248237798175 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Separately, Maxim Group restated a “buy” rating and issued a $7.00 price objective on shares of Immutep in a research note on Thursday, November 9th.

Immutep (IMMP) opened at $1.90 on Friday. The company has a quick ratio of 6.06, a current ratio of 6.06 and a debt-to-equity ratio of 0.22. Immutep has a 12 month low of $1.25 and a 12 month high of $3.24.

COPYRIGHT VIOLATION WARNING: This story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at

About Immutep

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with's FREE daily email newsletter.

Leave a Reply